Drug updated on 3/28/2024
| Dosage Form | Capsule (oral: 40 mg, 60 mg, 80 mg) |
| Drug Class | Vesicular monoamine transporter 2 inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adults with tardive dyskinesia.
- For the treatment of chorea associated with Huntington’s disease.
Summary
- Valbenazine (Ingrezza) is indicated for the treatment of adults with tardive dyskinesia and chorea associated with Huntington’s disease.
- A total of 6 systematic reviews/meta-analyses were reviewed to gather information about Ingrezza's efficacy, safety, tolerability, and acceptability in treating these conditions.
- Both valbenazine dosages (40mg/d and 80mg/d) showed superiority over placebo in terms of Abnormal Involuntary Movement Scale score reduction, Clinical Global Impression of Change-TD improvement, and response to treatment; however, the higher dosage demonstrated better results than the lower one without significant differences in acceptability or safety outcomes.
- Compared to another vesicular monoamine transporter 2 inhibitor deutetrabenazine used for tardive dyskinesia treatment, valbenazine exhibited robust efficacy at a dose of 80 mg/day both short-term and long-term while more data on long-term effects are needed for deutetrabenazine.
- Another review found that two VMAT-2 inhibitors including valbenzine effectively treated TD acutely as well as long term without increasing risk factors such as depression or suicide among patients suffering from chronic mental illnesses like schizophrenia.
- One study reported moderate-quality evidence suggesting that use of valbenzine may be effective in relieving symptoms related to tardive dyskinesia but emphasized need for further trials due its small sample size limitation.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Ingrezza (valbenazine) Prescribing Information. | 2023 | Neurocrine Biosciences, Inc., San Diego, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Valbenazine for tardive dyskinesia: a systematic review and network meta-analysis. | 2023 | International clinical psychopharmacology. |
| A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine. | 2019 | Therapeutic Advances in Psychopharmacology |
| A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine. | 2019 | Therapeutic Advances in Psychopharmacology |
| Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. | 2018 | Drug Design, Development and Therapy |
| Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review. | 2018 | Journal of Comparative Effectiveness Research |
| Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia. | 2018 | Cochrane Database of Systematic Reviews |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia third edition. | 2021 | American Psychiatric Association |